Potentially lifethreatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).
Oncol Rep
; 45(3): 891-898, 2021 03.
Article
in En
| MEDLINE
| ID: mdl-33650659
ABSTRACT
Tyrosine kinase inhibitors (TKIs) have emerged as a new frontier of cancer therapy. These agents include inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), BRAF, mitogenactivated protein kinase kinase (also referred to as MEK), bcrabl, cKIT, plateletderived growth factor (PDGFR), fibroblast growth factor receptor (FGFR), anaplastic lymphoma kinase (ALK) and vascular endothelial growth factor (VEGF). Along with the evolving applications of TKIs, there has been an increased recognition of the breadth of potential cutaneous toxicities to these agents. In this review, we provide an overview of potentially lifethreatening severe cutaneous adverse reactions (SCARs) that may occur during therapy with TKIs. These toxicities include StevensJohnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP).
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Protein-Tyrosine Kinases
/
Drug Eruptions
/
Protein Kinase Inhibitors
Type of study:
Diagnostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Oncol Rep
Journal subject:
NEOPLASIAS
Year:
2021
Document type:
Article
Affiliation country: